69 results about "Bacillus ehimensis" patented technology

The invention discloses a kit for quickly detecting 15 pneumonia pathogenic bacteria. The kit can detect streptococcus pneumoniae, staphylococcus aureus, haemophilus influenzae, mycoplasma pneumoniae, pseudomonas aeruginosa, baumanii, enterococcus faecalis, enterococcus faecium, klebsiella pneumoniae, escherichia coli, enterobacter cloacae, stenotrophomonas maltophilia, burkholderia cepacia, legionella pneumophila and chlamydia pneumoniae which cover clinically common pneumonia pathogenic bacteria difficult to culture. 16S rDNA and specific gene sequences corresponding to the pneumonia pathogenic bacteria are detected by combining gene chips with multiple asymmetric PCR reactions, and the categories of the bacteria in a to-be-detected sample are identified in genus and species. The kit makes up for the defect that current clinical detection of pneumonia pathogenic bacteria is not in time or comprehensive and a novel detection means for early diagnosis and early treatment of patients suffering from pneumonia is provided.

The invention provides a pathogen inspection reagent, and concretely discloses a primer probe combination and a kit for combined inspection of 15 kinds of respiratory tract infection pathogens. By aiming at specific target sequences of the gene sequence conserved region of klebsiella pneumoniae, haemophilus influenzae, streptococcus pyogenes, staphylococcus aureus, escherichia coli, chlamydia pneumoniae, mycobacterium tuberculosis, stenotrophomonas maltophilia, baumanii, mycoplasma pneumoniae, enterococcus faecalis, ligionella pneumohpillia, streptococcus pneumoniae, bacillus pyocyaneus and mycobacterium abscessus, primers and probes which do not have mutual crossed reaction are designed, so that the problem that detection probes of different pathogens can easily generate mutual influenceor interference is solved; the combination and matching of different primers and probes are ensured; the goal of simultaneously performing efficient specific inspection at the same temperature can also be achieved.

The invention relates to a multiplex PCR-based synchronous and rapid method for detecting 13 pathogenic microorganisms in water, which comprises the steps of using multiplex PCR to simultaneously amplify gene-specific fragments of the 13 pathogenic microorganisms including escherichia coli, enterohaemorragic escherichia coli o157:h7, legionella pneumophila, salmonella enteritidis, shigella dysenteriae, staphyloccocus aureus, listeria monoeytogenes, helicobacter pylori, mycobacterium tuberculosis, klebsiella pneumonia, vibrio cholera, bacillus anthracis and yersinia pestis, and detecting PCR amplified products through agarose gel electrophoresis, thereby achieving synchronous and rapid detection for the 13 pathogenic microorganisms.

Disclosed are a preparation method and application of Anaphalis lactea essential oil. Volatile oil in Anaphalis lacteal is extracted by steam distillation and CO2 supercritical extraction, ingredients of the volatile oil are analyzed initially by gas chromatography/mass spectrography, 57 ingredients in the volatile oil are identified and account for more than 94% of the total volatile oil. Antibacterial and bactericidal activities of the volatile oil are researched by the Oxford cup method, and according to the research, the volatile oil has an evident killing or inhibiting function for bacteria, such as staphylococcus, streptococcus, enterobacter, salmonella, shigella, pseudomonas, bacillus, escherichia coli and the like, and fungi, such as candida, cryptococcus, penicillin, aspergillus, mucor, microsporum, trichophyton, epidermophyton and the like. Testing by DPPH (diphenylpicrylhydrazyl) method shows that the volatile oil has fine antioxidant activity. Owing to the fine activity, the volatile oil is widely applicable to the industries of foods, medicines, cosmetics, health-care products and the like.

The invention relates herba dracocephalum heterophylli volatile oil possessing the bacteriostatic and germicidal action and its application. The method adopts steam distillation to extract the herba dracocephalum heterophylli volatile oil and adopts gas-chromatography/mass spectra to analysis the volatile oil, identifying the 83 components and 89.83% total content. The volatile oil can kill and suppress the staphylococcus, streptococcus, gonococcus, enterobacter, Escherichia, salmonella, shigella, pseudomonas, bacillus, oidiomycin, cryptococcus, aspergillus, penicillium, mucor, epidermophytin, micromonospora, trichophyton and other bacteriums. The herba dracocephalum heterophylli volatile oil is used for foodstuffs, drugs, health products, cosmetic products and other industries.

The invention discloses a gene chip-based method for synchronously and rapidly detecting thirteen pathogenic microorganisms in a water body. The method is characterized in that specific gene segments of the pathogenic microorganisms are amplified simultaneously by adopting multiple polymerase chain reactions (PCR), and then, a detection result is obtained through gene chip hybridization and chip scanning image analysis. The detected thirteen pathogenic microorganisms comprise escherichia coli, Enterohemorrhagic Escherichia coli O157:H7, legionella pneumophila, salmonella enteritidis, Shigella, staphylococcus aureus, Listeria monocytogenes, Helicobacter Pylori, mycobacterium tuberculosis, Klebsiella pneumonia, vibrio cholera, Bacillus anthracis and Yersinia pestis.

The invention discloses a broad spectrum type antimicrobial peptide (AMP) and application thereof and belongs to the technical field of medicine. The AMP is named 26 M, contains 18 amino acid residues, has a molecular weight of 2475.16 Daltons, has an isoelectric point of 12.03, and has an amino acid sequence shown in SEQ ID NO: 1. Experiments show that the AMP has the effect of significantly inhibiting the growth and reproduction of various pathogenic bacteria including Escherichia coli, Salmonella, Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, Streptococcus suis, Staphylococcus aureus, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium. The invention provides the novel AMP with a broad-spectrum antimicrobial effect,and the AMP can replace traditional antibiotics and cannot produce drug resistance easily, and has good application prospects in resisting infectious diseases caused by pathogenic bacteria.

The invention discloses a traditional Chinese medicinal composition for treating edema disease of a bamboo rat. The traditional Chinese medicinal composition consists of the following raw medicinal materials in parts by weight: 2-4 parts of cordate houttuynia, 2-4 parts of blackberry lily, 2-4 parts of dandelion, 2-4 parts of sculellaria barbata, 2-4 parts of coptis chinensis and 2-4 parts of root of Chinese pulsatilla, and the composition is prepared by mixing or decocting the various traditional Chinese medicinal raw materials after respectively grinding. The traditional Chinese medicinal composition has the functions of clearing away heat and toxic materials, relieving swelling and pain, resisting inflammation, stopping blooding, removing dampness, killing parasites and the like; the composition is good in antibacterial performance, has a relatively good effect on inhibiting or killing escherichia coli and not easy to result in drug resistance, and is capable of enhancing immunity of the bamboo rat, reducing use of biotic, avoiding abuse of the biotic and benefiting for health of the bamboo rat. The traditional Chinese medicinal composition has relatively high curative rate and effective rate on treating edema disease of the bamboo rat, and is stable in effectiveness; the composition is abundant in crude medicine resource, appropriate in proportion and convenient to use and has an obvious treatment effect.

The invention discloses an expression purification method of a mycobacterium tuberculosis fusion protein LT29. An active-period antigen EAST6 of mycobacterium tuberculosis and an incubation-period antigen Rv2626c of the mycobacterium tuberculosis are fused and connected by a flexible peptide fragment so as to construct the fusion protein ESAT6-linker-Rv2626c. The fusion protein is subjected to expression purification in escherichia coli B21 engineering bacteria, and is combined with an adjuvant DP to construct a tuberculosis subunit vaccine. The fusion protein is successfully expressed and purified in escherichia coli; strong specific cellular immunoreaction aiming at the specific antigens (ESAT6 and Rv2626c) of the mycobacterium tuberculosis can be induced to be generated in a mouse body, the generation of long-term memory T cells is promoted, and the fusion protein has strong immunogenicity. According to the invention, the novel fusion protein LT29 without a label is successfully constructed, expressed and purified, the protein fuses the active-period antigen and the incubation-period antigen of tubercle bacillus, antigen-specific cellular immunity and humoral immunity can be induced to be generated, and the novel fusion protein LT29 is expected to become an effective candidate vaccine for preventing and treating tuberculosis.

The invention discloses a plasma free DNA marker for bloodstream infection pathogen diagnosis. The invention provides a plasma free DNA treatment method comprising the following step: selecting a fragment with a size of 60-140 bp from to-be-tested plasma free DNA. The method can be used as a sample pretreatment method for bloodstream infection pathogen detection through the plasma free DNA. The distribution range of free nucleic acid in plasma samples infected with Escherichia coli, Klebsiella pneumoniae, staphylococcus aureus, enterococcus faecium and Acinetobacter baumannii is studied, and the distribution of free nucleic acid fragments of the five bacteria in plasma is determined. The plasma free DNA marker has important significance of improving the sensitivity of pathogen detection inplasma metagenome detection and guiding the design of the length range of PCR amplification product fragments to improve the PCR detection sensitivity. The plasma free DNA marker provides a basis forpreparation of pathogen simulation samples in a plasma free DNA detection product development process.

The invention discloses a soil repairing complex microbial inoculant for degrading soil fertilizer and medicine residues and a soil repairing method of the soil repairing complex microbial inoculant. The soil repairing complex microbial inoculant for degrading soil fertilizer and medicine residues comprises the following components in parts by weight: 2-6 parts of Tsuruhada delftia acidovorans, 2-6 parts of escherichia hermannii, 2-6 parts of bacillus subtilis, 2-6 parts of streptomycete, 1-5 parts of beer yeast and lactobacillus plantarum, 1-5 parts of acinetobacter, 1-5 parts of bacillus licheniformis and 1-5 parts of gordon amarae.

The invention discloses a mesoporous bioactive glass/lasiosphaera composite material, preparation and applications, and belongs to the biomedical material field. The composite material is mainly composed of mesoporous bioactive glass and lasiosphaera. The preparation technology method is advantaged by simple preparation, controllable technological parameters, convenient operation and low cost. The obtained composite material has good hemostatic effects. In addition, the composite material has certain inhibition effects on staphylococcus aureus, pseudomonas aeruginosa, proteusbacillus vulgaris, diplococcus pneumonia, typhoid bacillus and escherichia coli, has inhibition effects on few pathogenic fungi, has good biological activity, and can be used as an integrated composite material of antibiosis, hemostasis and promoting tissue regeneration.

The application provides a primer and/or probe composition for detecting bacillus for initiating blood flow infection and an application of the primer and/or probe composition, and particularly relates to one or more primer and/or probe compositions or relevant reagents or reagent kits for detecting mycobacterium tuberculosis, listeria monocytogenes, klebsiella pneumoniae, pseudomonas aeruginosa,baumanii, escherichia coli, haemophilus influenzae and proteus mirabilis, so that the detection period of the bacillus can be greatly shortened, the efficiency and the detection flux are improved, andthe primer and/or probe composition can meet detection requirements. In addition, the method and relevant products thereof disclosed by the application have high specificity, sensitivity and accuracy.

The invention relates to a microorganism for producing chitosanase, and a plant cultivation composition and cultivation method using the same, in particular to a lettuce cultivation method based on Paenibacillus mucilaginosus C23 (collected under KACC91963P) and Bacillus ehimensis (collected under KACC91964P); compared with traditional chitosan-decomposing microorganisms, the microorganism used in the method provided herein provides decomposition at higher speed; when a chitosan fermentation using the microorganism applies to lettuce cultivation, the microorganism promotes the growth and development of lettuce and adds more functional ingredients and functions (polyphenols, flavonoids and electron donating capacity).

A method of controlling the presence of bacteria that belong to the group of enterobacteriaceae, for example, Salmonella and/or Escherichia species, in a monogastric animal, by feeding the monogastric animal with a feed material that comprises mycelium of Agaricus Blazei Murill (ABM mycelium), e.g., grown on a grain substrate.

The invention belongs to the technical field of medicines. The invention relates to an antibacterial composition containing avibactam and meropenem and application thereof. Particularly, the inventionprovides application of avibactam or a pharmaceutically acceptable salt thereof and meropenem in preparation of a medicine for treating or preventing bacterial infection, in particular to applicationin preparation of medicines for treating infection caused by escherichia coli, pseudomonas aeruginosa, klebsiella pneumoniae, acinetobacter baumannii and enterobacter aerogenes, and aims to solve theproblem of drug resistance of carbapenem antibiotics.